<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031962</url>
  </required_header>
  <id_info>
    <org_study_id>BR_01_CIP</org_study_id>
    <nct_id>NCT05031962</nct_id>
  </id_info>
  <brief_title>Safety and Clinical Performance of a Biological Matrix Used in Implant-based Breast Reconstruction</brief_title>
  <official_title>Porcine Acellular Dermal Matrix (PADM)-Assisted Implant-based Breast Reconstruction: a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meccellis Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meccellis Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of the study is to confirm the medium/long-term safety and clinical&#xD;
      performance of the CELLIS Breast membranes used in breast reconstruction and to identify&#xD;
      emerging risks in comparison to clinical data related to other treatment modalities.&#xD;
&#xD;
      The present study will be a prospective, multicentric, non-randomized and non-controlled&#xD;
      trial involving 112 patients followed for 24 months. The study will be conducted in France in&#xD;
      7 investigational centres.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be prospective, multicentric, single-arm observational (non-interventional) to&#xD;
      evaluate the safety and performance of the CELLIS Breast membranes used in breast&#xD;
      reconstruction following mastectomy.&#xD;
&#xD;
      All evaluations will be performed and products used according to the usual practice, without&#xD;
      additional or unusual diagnostic, treatment and monitoring procedure.&#xD;
&#xD;
      The study will be conducted in France in 7 investigational centres including 112 patients&#xD;
      scheduled for a breast reconstruction following mastectomy.&#xD;
&#xD;
      Each patient will participate in one assessment period including a preoperative visit,&#xD;
      followed by the day of surgical procedure and a hospitalization period.&#xD;
&#xD;
      Patients will return for ambulatory visits on day 10 (+/- 5 days) and/or on day 30 (+/- 7&#xD;
      days), on month 3 (+/- 2 weeks), on month 12 (+/- 2 weeks) and on month 24 (+/-2 weeks)&#xD;
      post-surgery.&#xD;
&#xD;
      CELLIS Breast is available in one thickness, in a variety of size and forms addressing&#xD;
      multiple surgical techniques.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adverse events. Main complications of interest: infection, cellulitis, seroma, hematoma, skin flap-nipple necrosis, delayed wound healing, wound dehiscence, red breast syndrome, capsular contracture, implant related</measure>
    <time_frame>From the surgical procedure throughout the entire 24-month follow-up period</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient aesthetic evaluation evaluated by Visual Analog Scale (VAS). The suppleness of the reconstruction will be evaluated (natural-hard): VAS score from 1 to 10 (1=very bad suppleness, breast hard; 10=excellent suppleness-natural breast).</measure>
    <time_frame>At the 3, 12 and 24-month follow-up visits</time_frame>
    <description>Described at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon aesthetic evaluation: satisfaction related to the quality of the reconstruction (very good, good, fair, bad), suppleness (Visual Analog Scale score from 1 to 10 with 10=excellent suppleness) and symmetry (very good, good, fair, bad).</measure>
    <time_frame>At the 3, 12 and 24-month follow-up visits</time_frame>
    <description>Percentage of each modality and VAS score described at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported pain using a visual analogue scale (VAS) scored from 0 to 10 (0=no pain; 10=worse pain).</measure>
    <time_frame>At the 10-day, 30-day, 3-month, 12-month and 24-month follow-up visits</time_frame>
    <description>Described at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient analgesics consumption</measure>
    <time_frame>At the 10-day, 30-day, 3-month, 12-month and 24-month follow-up visits</time_frame>
    <description>Percentage of analgesics consumption with a Cochrane-Armitage trend test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) by the use of the SF-36 questionnaire.</measure>
    <time_frame>At baseline and at 24 month</time_frame>
    <description>Change from screening of each domain score and total score at 24-month. The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 with lower scores = more disability, and higher scores = less disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of device deficiency: inadequacy of a medical device with respects to its identity, quality, durability, reliability, safety or performance. Device deficiencies include malfunctions, use errors, and inadequate labelling.</measure>
    <time_frame>During the surgical procedure</time_frame>
    <description>Summarized and listed</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Breast Reconstruction Following Mastectomy</condition>
  <arm_group>
    <arm_group_label>CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)</arm_group_label>
    <description>Implant-based breast reconstruction following mastectomy using the CELLIS Breast matrix</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)</intervention_name>
    <description>Biological membrane used in breast reconstruction</description>
    <arm_group_label>CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Constitution and follow-up of a consecutive cohort of patients operated with the CELLIS&#xD;
        Breast membranes based on the usual practices, the indication and the inclusion-exclusion&#xD;
        criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged ≥18 years,&#xD;
&#xD;
          -  Patient with an indication of breast reconstruction after mastectomy (therapeutic or&#xD;
             prophylactic),&#xD;
&#xD;
          -  Patient being informed of her participation to the study and of the follow-up visits,&#xD;
             and having no objection to the clinical data collection and medical file access,&#xD;
&#xD;
          -  Patient being informed of the porcine origin of the device in advance of the&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with known hypersensitivity to porcine materials,&#xD;
&#xD;
          -  Patient with an existing infection at the site of implantation,&#xD;
&#xD;
          -  Patient having refused to participate to the study,&#xD;
&#xD;
          -  Patient refusing to return for the follow-up visits,&#xD;
&#xD;
          -  Patient who is pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael ATLAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Tenon, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire CISTERNI, PhD</last_name>
    <phone>+33 (0)6 68 13 76 26</phone>
    <email>claire.cisterni@meccellis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillaume HOFMANSKI</last_name>
    <phone>+33 (0)7 61 31 11 33</phone>
    <email>guillaume.hofmanski@meccellis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>HIVELIN Mikael, MD</last_name>
    </contact>
    <investigator>
      <last_name>HIVELIN Mikael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Cavale Blanche, CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>ROUANET Marion, MD</last_name>
    </contact>
    <investigator>
      <last_name>HU Weiguo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ROUANET Marion, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>SCHOHN Thomas, MD</last_name>
    </contact>
    <investigator>
      <last_name>SCHOHN Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>LAPORTE Julie, MD</last_name>
    </contact>
    <investigator>
      <last_name>LAPORTE Julie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>TAVEAU Corentin, MD</last_name>
    </contact>
    <investigator>
      <last_name>LANTIERI Laurent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>TAVEAU Corentin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>ATLAN Michael, MD</last_name>
    </contact>
    <investigator>
      <last_name>ATLAN Michael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>GANGLOFF Dimitri, MD</last_name>
    </contact>
    <investigator>
      <last_name>GANGLOFF Dimitri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast reconstruction</keyword>
  <keyword>Biological membrane</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

